nach oben

Erschienen in:

01.07.2011 | Original Article

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

verfasst von: Nikolaos Xenidis, Nikolaos Vardakis, Ioannis Varthalitis, Stylianos Giassas, Emmanouel Kontopodis, Nikolaos Ziras, Ioannis Gioulbasanis, George Samonis, Kostas Kalbakis, Vassilis Georgoulias

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate efficacy and toxicity of a combination of pegylated liposomal doxorubicin and irinotecan in patients with refractory small-cell lung cancer.

Patients and methods

Thirty-one patients with early relapse after first-line therapy with cisplatin/etoposide were treated with pegylated liposomal doxorubicin 15 mg/m² and irinotecan 125 mg/m² on days 1 and 15. Treatment was repeated every 28 days.

Results

A total of 144 chemotherapy courses were administered. All patients were evaluable for toxicity and twenty-six (84%) for response. Grade 3 neutropenia occurred in two (6.5%) patients and grade 1 thrombocytopenia in one (3.2%). Fatigue was the most frequent grade 3 non-hematologic toxicity and was observed in seven patients (23%). Four (12.9; 95% CI: 1.1–24.7%) patients achieved a partial response, and disease stabilization was observed in additional two (6.5%) patients (Tumor Growth Control: 19.4; 95% CI: 5.5–33.3%). The median TTP was 2.03 months, and the median survival time was 3.16 months.

Conclusions

The combination of pegylated doxorubicin and irinotecan is very well tolerated but with modest activity in patients with refractory SCLC.

Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845PubMedCrossRef

Brahmer JR, Ettinger DS (1998) Carboplatin in the treatment of small cell lung cancer. Oncologist 3:143–154PubMed

Pujol JL, Carestia L, Daures JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8–15PubMedCrossRef

Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366:1385–1396PubMedCrossRef

Huisman C, Postmus PE, Giaccone G, Smit EF (1999) Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 25:199–206PubMedCrossRef

Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W (1987) Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23:1409–1411PubMedCrossRef

Hurwitz JL, McCoy F, Scullin P, Fennell DA (2009) New advances in the second-line treatment of small cell lung cancer. Oncologist 14:986–994PubMedCrossRef

Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH (1999) Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 5:3645–3652PubMed

Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA (2006) Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer 52:327–332PubMedCrossRef

10.

Carboni MC, Coderoni S (1994) Effect of CPT on the DNA cleavage/religation reaction mediated by calf thymus Topoisomerase I: evidence of an inhibition of DNA religation. Inhibition of Topoisomerase I-mediated DNA religation by CPT. Mol Biol Rep 20:129–133PubMedCrossRef

11.

Natale R, Lara P, Chansky K (2008) S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol 26(20 suppl) (Ref Type: Abstract)

12.

Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225–1229PubMed

13.

Sandler A (2002) Irinotecan plus cisplatin in small-cell lung cancer. Oncology (Williston Park) 16:39–43

14.

Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M (1998) Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16:3329–3334PubMed

15.

Rocha-Lima CM, Herndon JE, Lee ME, Atkins JN, Mauer A, Vokes E, Green MR (2007) Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 18:331–337PubMedCrossRef

16.

Cortes F, Pinero J (1994) Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemother Pharmacol 34:411–415PubMedCrossRef

17.

Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, Rizvi N, Teicher BA (1998) Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 42:327–335PubMedCrossRef

18.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

19.

Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47PubMedCrossRef

20.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef

21.

Tiseo M, Ardizzoni A (2007) Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2:764–772PubMedCrossRef

22.

Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y (2008) Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 113:2518–2523PubMedCrossRef

23.

Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S (2005) Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48:251–261PubMedCrossRef

24.

Cheng S, Evans WK, Stys-Norman D, Shepherd FA (2007) Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2:348–354PubMedCrossRef

25.

Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401–5406PubMedCrossRef

26.

Nogami N, Kiura K, Takigava N, Harita S, Chikamori K, Shibayama T, Tabata M, Hotta K, Shinkai T, Tanimoto M (2010) A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC). J Clin Oncol 28:15s (Ref Type: Abstract)

Titel: Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
verfasst von: Nikolaos Xenidis
Nikolaos Vardakis
Ioannis Varthalitis
Stylianos Giassas
Emmanouel Kontopodis
Nikolaos Ziras
Ioannis Gioulbasanis
George Samonis
Kostas Kalbakis
Vassilis Georgoulias
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1427-5

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer